ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy

NCT02609958 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

ASLAN Pharmaceuticals